[Neuroblastoma]

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2005 May 19

PMID 15899223

Citations 1

Authors

Victoria Castel

Adela Canete

Rosa Noguera

Samuel Navarro

Silvestre Oltra

Affiliations

Soon will be listed here.

Citing Articles

Neuroblastoma in adolescents: genetic and clinical characterisation.

Castel V, Villamon E, Canete A, Navarro S, Ruiz A, Melero C Clin Transl Oncol. 2010; 12(1):49-54.

PMID: 20080471 DOI: 10.1007/s12094-010-0466-z.

References

Woods W, Tuchman M, Robison L, Bernstein M, Leclerc J, Brisson L . A population-based study of the usefulness of screening for neuroblastoma. Lancet. 1996; 348(9043):1682-7. DOI: 10.1016/S0140-6736(96)06020-5. View

Matthay K, Perez C, Seeger R, Brodeur G, Shimada H, Atkinson J . Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol. 1998; 16(4):1256-64. DOI: 10.1200/JCO.1998.16.4.1256. View

Tweddle D, Pinkerton C, Lewis I, Ellershaw C, Cole M, Pearson A . OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age. Med Pediatr Oncol. 2001; 36(1):239-42. DOI: 10.1002/1096-911X(20010101)36:1<239::AID-MPO1058>3.0.CO;2-G. View

Pritchard J, Cotterill S, Germond S, Imeson J, de Kraker J, Jones D . High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer. 2004; 44(4):348-57. DOI: 10.1002/pbc.20219. View

Matthay K, Seeger R, Reynolds C, Stram D, OLeary M, Harris R . Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer Group. J Clin Oncol. 1994; 12(11):2382-9. DOI: 10.1200/JCO.1994.12.11.2382. View

Squire J, Thorner P, Weitzman S, Maggi J, Dirks P, Doyle J . Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma. Oncogene. 1995; 10(7):1417-22. View

Tchirkov A, Paillard C, Halle P, Bernard F, Bordigoni P, Vago P . Significance of molecular quantification of minimal residual disease in metastatic neuroblastoma. J Hematother Stem Cell Res. 2003; 12(4):435-42. DOI: 10.1089/152581603322286060. View

Katzenstein H, Bowman L, Brodeur G, Thorner P, JOSHI V, SMITH E . Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study. J Clin Oncol. 1998; 16(6):2007-17. DOI: 10.1200/JCO.1998.16.6.2007. View

Brodeur G, Pritchard J, Berthold F, Carlsen N, Castel V, Castelberry R . Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993; 11(8):1466-77. DOI: 10.1200/JCO.1993.11.8.1466. View

10.

Spitz R, Hero B, Ernestus K, Berthold F . FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma. Med Pediatr Oncol. 2003; 41(1):30-5. DOI: 10.1002/mpo.10313. View

11.

Hsu L, Evans A, DAngio G . Hepatomegaly in neuroblastoma stage 4s: criteria for treatment of the vulnerable neonate. Med Pediatr Oncol. 1996; 27(6):521-8. DOI: 10.1002/(SICI)1096-911X(199612)27:6<521::AID-MPO3>3.0.CO;2-N. View

12.

Hoefnagel C . Nuclear medicine therapy of neuroblastoma. Q J Nucl Med. 2000; 43(4):336-43. View

13.

Evans A, DAngio G, Sather H, DE LORIMIER A, Dalton A, Ungerleider R . A comparison of four staging systems for localized and regional neuroblastoma: a report from the Childrens Cancer Study Group. J Clin Oncol. 1990; 8(4):678-88. DOI: 10.1200/JCO.1990.8.4.678. View

14.

Schwab M, Westermann F, Hero B, Berthold F . Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol. 2003; 4(8):472-80. DOI: 10.1016/s1470-2045(03)01166-5. View

15.

Schwab M, Ellison J, Busch M, Rosenau W, Varmus H, Bishop J . Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci U S A. 1984; 81(15):4940-4. PMC: 391608. DOI: 10.1073/pnas.81.15.4940. View

16.

Plantaz D, Rubie H, Michon J, Mechinaud F, Coze C, Chastagner P . The treatment of neuroblastoma with intraspinal extension with chemotherapy followed by surgical removal of residual disease. A prospective study of 42 patients--results of the NBL 90 Study of the French Society of Pediatric Oncology. Cancer. 1996; 78(2):311-9. DOI: 10.1002/(SICI)1097-0142(19960715)78:2<311::AID-CNCR19>3.0.CO;2-Z. View

17.

Kaneko M, Tsuchida Y, Mugishima H, Ohnuma N, Yamamoto K, Kawa K . Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol. 2002; 24(8):613-21. DOI: 10.1097/00043426-200211000-00004. View

18.

Shimada H, Ambros I, Dehner L, Hata J, JOSHI V, Roald B . The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999; 86(2):364-72. View

19.

Haber M, Bordow S, Haber P, Marshall G, Stewart B, Norris M . The prognostic value of MDR1 gene expression in primary untreated neuroblastoma. Eur J Cancer. 1998; 33(12):2031-6. DOI: 10.1016/s0959-8049(97)00229-3. View

20.

Stanton L, Schwab M, Bishop J . Nucleotide sequence of the human N-myc gene. Proc Natl Acad Sci U S A. 1986; 83(6):1772-6. PMC: 323166. DOI: 10.1073/pnas.83.6.1772. View